BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18612934)

  • 1. Membranous glomerulopathy associated with rheumatoid arthritis may respond to rituximab.
    Pixley J; Wolf B; O'Neill W
    Scand J Rheumatol; 2008; 37(4):313-4. PubMed ID: 18612934
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.
    Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab for treatment of scleritis associated with rheumatoid arthritis.
    Chauhan S; Kamal A; Thompson RN; Estrach C; Moots RJ
    Br J Ophthalmol; 2009 Jul; 93(7):984-5. PubMed ID: 19553514
    [No Abstract]   [Full Text] [Related]  

  • 6. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
    Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
    Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis.
    Hellmann M; Jung N; Owczarczyk K; Hallek M; Rubbert A
    Rheumatology (Oxford); 2008 Jun; 47(6):929-30. PubMed ID: 18411212
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rituximab: a new therapeutic arm in refractory rheumatoid arthritis: about one case].
    Abdelmoula LC; Testouri N; Ben Hadj Yahia C; Tekaya R; Ben M'barek R; Chaabouni L; Zouari R
    Tunis Med; 2008 Sep; 86(9):841-2. PubMed ID: 19472790
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
    Burr ML; Malaviya AP; Gaston JH; Carmichael AJ; Ostör AJ
    Rheumatology (Oxford); 2008 May; 47(5):738-9. PubMed ID: 18375402
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab.
    Maher LV; Wilson JG
    Rheumatology (Oxford); 2006 Nov; 45(11):1450-1. PubMed ID: 16936329
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rituximab (Mabthera)--new approach in treatment of rheumatoid arthritis].
    Anić B
    Reumatizam; 2007; 54(2):72-3. PubMed ID: 18351146
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.
    Risselada A; Tekstra J; Teng YK; Welsing PM; Breedveld F; van Laar JM; Bijlsma JW
    Ann Rheum Dis; 2010 Oct; 69(10):1891-2. PubMed ID: 20444758
    [No Abstract]   [Full Text] [Related]  

  • 14. Rheumatoid arthritis treatment progressing.
    Health News; 2004 Aug; 10(8):9. PubMed ID: 15551458
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab for idiopathic membranous nephropathy: who can benefit?
    Ruggenenti P; Chiurchiu C; Abbate M; Perna A; Cravedi P; Bontempelli M; Remuzzi G
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):738-48. PubMed ID: 17699281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
    Soriano ER; Galarza-Maldonado C; Cardiel MH; Pons-Estel BA; Massardo L; Caballero-Uribe CV; Achurra-Castillo AF; Barile-Fabris LA; Chávez-Corrales J; Díaz-Coto JF; Esteva-Spinetti MH; Guibert-Toledano M; Palazuelos FI; Keiserman MW; Lomonte AV; Mota LM; Pineda Villaseñor C; Alarcón GS;
    Rheumatology (Oxford); 2008 Jul; 47(7):1097-9. PubMed ID: 18463144
    [No Abstract]   [Full Text] [Related]  

  • 17. [Administration of rituximab in rheumatoid arthritis from the position of evidence-based medicine].
    Nasonov EL
    Ter Arkh; 2007; 79(12):76-82. PubMed ID: 18220039
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer drug approved for RA.
    Health News; 2006 Apr; 12(4):2. PubMed ID: 16572516
    [No Abstract]   [Full Text] [Related]  

  • 19. Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab.
    Schmid L; Müller M; Treumann T; Arnold W; Möller B; Aeberli D; Villiger PM
    Arthritis Rheum; 2009 Jun; 60(6):1632-4. PubMed ID: 19479865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
    Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.